News >

Frontline Osimertinib Approved in Europe for EGFR-mutant NSCLC

Silas Inman @silasinman
Published: Monday, Jun 11, 2018

David Planchard MD, PhD

David Planchard MD, PhD
The European Commission has approved osimertinib (Tagrisso) as a frontline treatment for patients with EGFR-mutant locally-advanced or metastatic non–small cell lung cancer (NSCLC), based on data from the phase III FLAURA trial.

T790M-positive NSCLC. Findings from the phase III AURA3 trial subsequently validated these approvals, which were based on early phase clinical trials.
Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378:113-125.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication